LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Response to Public Consultation on Horizon Europe – interim evaluation

23/02/2023
OTHER

EuropaBio provided input to the European Commission’s interim evaluation of Horizon Europe. The EU should continue to develop the various pillars of Horizon Europe to make full use of its scientific and industrial excellence and to help foster a stronger and more resilient research and innovation ecosystem for biotechnology across Europe.

Industrial biotechnology is an important enabling technology for a more competitive, sustainable, and circular European bioeconomy. As such, it is important that the European R&I Framework Programme including the upcoming Strategic Plan of Horizon Europe (2025 – 2027) continues to focus on and fund activities that are relevant for this sector and the bioeconomy more widely. Advances in industrial biotechnology, and wider adoption and use of biotechnology, can contribute to Europe’s green ambitions, energy security, competitiveness, and resilience in the face of global geopolitical instability and large-scale disruptions, as well as maintain Europe’s position in the world as a technological leader. Similarly, investments made through the different pillars and structures of Horizon Europe into infrastructure for scale-up, skills development, and the development of regulatory and standards frameworks for industrial biotechnology innovation are critical.

The bioeconomy is cross-sectoral in nature and therefore presents opportunities for synergies between different R&I clusters. By seeking new ways of production, powered by sustainable resource management, innovation in industrial biotechnology supports the development of economic and industrial activities which respect planetary boundaries. This contributes towards bringing the EU closer to its goal of developing a circular bioeconomy. In this context, it is therefore relevant to consider the role and potential of the bioeconomy and bio-based innovations (mainly grouped under Cluster 6 in Horizon Europe) and how these overlap with activities in other areas such as climate, industry, and health (which are grouped under separate Clusters).

On the identification of funding priorities more broadly, areas, where successful R&I funding could contribute to solutions to energy security, manufacturing capacity and supply chain resilience, should be prioritized. Research and innovation in biotechnology have the potential to bring creative, unique and important solutions to make European societies healthier, more sustainable, and tackle many other systemic and global challenges we face in the 21st century.

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
25/06/2025

Hawkwood Biotech joins EuropaBio: Supporting Industrial Biotech with their Critical Challenges


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.